RxDoctor Payments Data

Madison Masters, PA

Physician Assistant · South Lyon, MINPI 1477120426

Payments from drug & device makers

$7,007in general payments, 2019–2025

Across 406 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$710
  • Takeda Pharmaceuticals U.S.A., Inc.$655
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$635
  • Ardelyx, Inc.$440
  • UCB, Inc.$257
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,66695%
  • Education$3405%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,007 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$44,638
Medicare patients
256
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide112$89,922
XifaxanRifaximin21$68,741
IbsrelaTenapanor Hcl20$33,578
Mesalamine16$4,826
Omeprazole395$4,391
Sucralfate29$3,625
Famotidine340$2,804
Ursodiol16$2,397
Esomeprazole Magnesium26$1,762
Dicyclomine Hcl103$1,624
Pantoprazole Sodium161$1,451
Lactulose18$340
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg13$272
Propranolol Hcl23$250
Metoclopramide Hcl35$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,176$89,922112 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$635$68,74121 claims
Ardelyx, Inc.Ibsrela$440$33,57820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in South Lyon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →